5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

5537 Background: The epidermal growth factor receptor (EGFR) is expressed in nearly all
SCCHN and carries a strong prognostic significance, providing the rationale for using EGFR …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

5567 Background: Cetuximab in combination with platinum and 5FU has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

5505 Background: Cetuximab in combination with platinum and 5FU (PFEx) has become a
standard in first-line treatment of patients (pts) with R/M SCCHN. Cetuximab and taxane …

Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …